These findings suggest that PD-L1 expression on tumor cells suppressed TRuC T cell activity, which could be overcome by engagement of the PD-1-CD28 with PD-L1 or the neutralizing effect of the anti-PD-L1 antibody (Fig. 2b). Here, PDCD1 is linked to neoplasm.